M
Mars B. van't Veer
Researcher at University of Paris
Publications - 21
Citations - 4128
Mars B. van't Veer is an academic researcher from University of Paris. The author has contributed to research in topics: Population & Survival rate. The author has an hindex of 16, co-authored 19 publications receiving 3850 citations. Previous affiliations of Mars B. van't Veer include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
Berthe M.P. Aleman,Alexandra W. van den Belt-Dusebout,Willem J. Klokman,Mars B. van't Veer,Harry Bartelink,Flora E. van Leeuwen +5 more
TL;DR: The main cause of death among HD patients was lymphoma, but after 20 years, HD mortality was negligible, and the RRs and AERs of death from second primary cancers (SCs) and CVDs continued to increase after 10 years.
Journal ArticleDOI
Late cardiotoxicity after treatment for Hodgkin lymphoma
Berthe M.P. Aleman,Alexandra W. van den Belt-Dusebout,Marie L. De Bruin,Mars B. van't Veer,Margreet H.A. Baaijens,Jan de Boer,Augustinus A. M. Hart,Willem J. Klokman,Marianne A. Kuenen,Gabey M. Ouwens,Harry Bartelink,Flora E. van Leeuwen +11 more
TL;DR: Risks of several CVDs are 3- to 5-fold increased in survivors of HL compared with the general population, even after prolonged follow-up, leading to increasing absolute excess risks over time.
Journal ArticleDOI
Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin’s Disease: A Population-Based Evaluation Over 25 Years
Graça M. Dores,Catherine Metayer,Rochelle E. Curtis,Charles F. Lynch,E. Aileen Clarke,Bengt Glimelius,Hans H. Storm,Eero Pukkala,Flora E. van Leeuwen,Eric Holowaty,Martin Andersson,Tom Wiklund,Timo Joensuu,Mars B. van't Veer,Marilyn Stovall,Mary Gospodarowicz,Lois B. Travis +16 more
TL;DR: Although significantly elevated risks of stomach, female breast, and uterine cervix cancers persisted for 25 years, an apparent decrease in relative risk and AER of solid tumors at other sites is suggested.
Journal ArticleDOI
Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.
Flora E. van Leeuwen,Willem J. Klokman,Mars B. van't Veer,Anton Hagenbeek,Augustinus D.G. Krol,Ursula A. O. Vetter,Michael Schaapveld,Peter van Heerde,J. Marion V. Burgers,R. Somers,Berthe M.P. Aleman +10 more
TL;DR: After more than 20 years of follow-up, the risk of solid tumors is still much greater in survivors of HD than in the population at large, and chemotherapy may increase the risk in patients who were young at the first treatment.
Journal ArticleDOI
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
Christophe Fermé,Houchingue Eghbali,J.H. Meerwaldt,Chantal Rieux,Jacques Bosq,Françoise Berger,Theodore Girinsky,Pauline Brice,Mars B. van't Veer,Jan Walewski,Pierre Lederlin,Umberto Tirelli,Patrice Carde,Eric Van Den Neste,Emmanuel Gyan,Mathieu Monconduit,Marine Diviné,John M. M. Raemaekers,Gilles Salles,Evert M. Noordijk,Geert Jan Creemers,Jean Gabarre,Anton Hagenbeek,Oumedaly Reman,Michel Blanc,José Thomas,B. Vie,Johanna Kluin-Nelemans,Fernando Viseu,Joke W. Baars,Philip Poortmans,Pieternella J. Lugtenburg,Christian Carrie,Jérôme Jaubert,Michel Henry-Amar +34 more
TL;DR: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features and in patients with unfavorable features, four courses of chemotherapyplus involved- field radiotherapy ought to be thestandard treatment.